February 15, 2018 / 4:15 PM / 3 months ago

BRIEF-Daré Bioscience Announces Effective License, Collaboration Deal For Topical Sildenafil

Feb 15 (Reuters) - Dare Bioscience Inc:

* DARÉ BIOSCIENCE, INC. ANNOUNCES EFFECTIVE LICENSE AND COLLABORATION AGREEMENT FOR TOPICAL SILDENAFIL FOR FEMALE SEXUAL AROUSAL DISORDER

* DARE BIOSCIENCE SAYS MET FUNDING REQUIREMENT FOR OBTAINING EXCLUSIVE WORLDWIDE LICENSE TO ADVANCE SST-6007 (5% TOPICAL SILDENAFIL CITRATE CREAM)

* DARE BIOSCIENCE - PLANS TO PURSUE 505(B)(2) REGULATORY PATHWAY FOR SST-6007 IN U.S.

* DARE BIOSCIENCE - FUNDS WILL BE USED TO ADVANCE SST-6007 (5% TOPICAL SILDENAFIL CITRATE CREAM) THROUGH NEXT PHASE OF CLINICAL DEVELOPMENT

* DARE BIOSCIENCE INC - ANTICIPATES COMMENCING A PHASE 2B CLINICAL TRIAL FOR SST-6007 IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below